CBIH (Cannabis Bioscience International Holdings) Moat Score: 1/10 (As of Aug. 03, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cannabis Bioscience International Holdings Moat Score?

Cannabis Bioscience International Holdings CBIH +33.33% Moat Score is 1 as of Aug. 03, 2026. The stock has 4 warning signs investors should review. Among 1,029 Drug Manufacturers companies, Cannabis Bioscience International Holdings ranks better than 76.38% on this metric.

Cannabis Bioscience International Holdings has the Moat Score of 1, which implies that the company might have No Moat - Very weak/transient advantages.

Cannabis Bioscience International Holdings has No Moat: CBIH operates in a highly competitive and fragmented cannabis market with low barriers to entry. It lacks significant market share, brand strength, or proprietary technology, resulting in minimal competitive advantages.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Cannabis Bioscience International Holdings might have No Moat - Very weak/transient advantages.

Cannabis Bioscience International Holdings  (OTCPK:CBIH) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Cannabis Bioscience International Holdings Moat Score Related Terms

CBIH vs SXTC, UPC, NPHC: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cannabis Bioscience International Holdings's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cannabis Bioscience International Holdings Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cannabis Bioscience International Holdings's Moat Score distribution charts can be found below:

* The bar in red indicates where Cannabis Bioscience International Holdings's Moat Score falls into.


Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 1 mean?
Cannabis Bioscience International Holdings (CBIH) has a Moat Score of 1 as of Aug. 03, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Cannabis Bioscience International Holdings ranks #243 out of 1029 companies in the Drug Manufacturers industry, placing it in the top 23.6%.
Is Cannabis Bioscience International Holdings' Moat Score too high?
Cannabis Bioscience International Holdings' current Moat Score is 1. Based on the distribution chart, Cannabis Bioscience International Holdings ranks #243 out of 1029 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Cannabis Bioscience International Holdings' Moat Score compare to SXTC and UPC?
According to the Drug Manufacturers industry distribution chart, Cannabis Bioscience International Holdings ranks #243 out of 1029 companies for Moat Score. This places Cannabis Bioscience International Holdings in the top 24% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Cannabis Bioscience International Holdings's current Moat Score is 1. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannabis Bioscience International Holdings stock overvalued right now?
Cannabis Bioscience International Holdings (CBIH) has a current Moat Score of 1. The current Moat Score is 1. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Cannabis Bioscience International Holdings (CBIH), the current Moat Score is 1 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cannabis Bioscience International Holdings Business Description

Address 6201 Bonhomme Road, Suite 435N, Houston, TX, USA, 77036
Cannabis Bioscience International Holdings Inc operates in three main areas. Firstly, the company engages in cannabis-related research and education under the trade name Pharmacology University. Secondly, it serves as both a Sponsor and a Contract Research Organization (CRO) in clinical trials, some of which involve cannabis and CBD products, under the trade name Alpha Research Institute. Lastly, the company plans to manufacture, market, and sell CBD products branded as "VitaCookies." The majority of the company's revenue comes from clinical trial contracts, while a smaller portion is generated from cannabis-related educational classes and seminars.